Literature DB >> 16604392

Latanoprost nonresponders with open-angle glaucoma in the Japanese population.

Yoko Ikeda1, Kazuhiko Mori, Takeshi Ishibashi, Shigeta Naruse, Nobuko Nakajima, Shigeru Kinoshita.   

Abstract

PURPOSE: As some patients show little response to latanoprost, one of the most powerful topical glaucoma medications, we investigated the incidence and clinical profiles of latanoprost nonresponders (LNR) in the Japanese population.
METHODS: We examined 62 glaucoma patients (62 eyes) who had received only latanoprost for more than 3 months. Their mean age was 63.8 +/- 1.8 years; the mean observation period was 9.7 +/- 0.4 months. At 1, 3, 6, and 12 months, their intraocular pressure (IOP) was measured, and the IOP reduction rate (RR) and the rate of LNR, defined as RR of 10% or less, were calculated. We statistically analyzed clinical factors involved in the LNR status of our study population.
RESULTS: At 1, 3, 6, and 12 months, RR was 20.1 +/- 2.0%, 18.8 +/- 2.3%, 21.1 +/- 2.8%, and 23.0 +/- 2.6%, respectively. At the same time points, the LNR incidence was 23.1%, 28.1%, 23.5%, and 31.8%, respectively, and significantly higher in patients whose baseline IOP was less than 15 mmHg. Patient sex and age and the glaucoma type played no significant role in the LNR status.
CONCLUSIONS: The incidence of LNR in the Japanese population, including normal-tension glaucoma (NTG) patients, is higher than among European or American patients. Only low baseline IOP was a significant clinical factor among LNR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16604392     DOI: 10.1007/s10384-005-0293-x

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.211


  29 in total

1.  Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma.

Authors:  M Saito; R Takano; S Shirato
Journal:  Am J Ophthalmol       Date:  2001-10       Impact factor: 5.258

2.  A retrospective review of non-responders to latanoprost.

Authors:  Warren J Scherer
Journal:  J Ocul Pharmacol Ther       Date:  2002-06       Impact factor: 2.671

3.  A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.

Authors:  H B DuBiner; M Mroz; A M Shapiro; M S Dirks
Journal:  Clin Ther       Date:  2001-12       Impact factor: 3.393

4.  Effect of trabeculectomy on visual field performance in central 30 degrees field in progressive normal-tension glaucoma.

Authors:  N Koseki; M Araie; S Shirato; S Yamamoto
Journal:  Ophthalmology       Date:  1997-02       Impact factor: 12.079

5.  Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost.

Authors:  Robert D Williams
Journal:  Adv Ther       Date:  2002 Nov-Dec       Impact factor: 3.845

6.  Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

Authors:  P G Watson
Journal:  Ophthalmology       Date:  1998-01       Impact factor: 12.079

7.  Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.

Authors:  P A Netland; T Landry; E K Sullivan; R Andrew; L Silver; A Weiner; S Mallick; J Dickerson; M V Bergamini; S M Robertson; A A Davis
Journal:  Am J Ophthalmol       Date:  2001-10       Impact factor: 5.258

8.  Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France.

Authors:  L M Bernard; R Althin; R Dhawan; D T Grima; A Lam; S Aballéa
Journal:  Eur J Ophthalmol       Date:  2003-07       Impact factor: 2.597

9.  Epidemiology of glaucoma in Japan--a nationwide glaucoma survey.

Authors:  Y Shiose; Y Kitazawa; S Tsukahara; T Akamatsu; K Mizokami; R Futa; H Katsushima; H Kosaki
Journal:  Jpn J Ophthalmol       Date:  1991       Impact factor: 2.447

10.  Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents.

Authors:  B Resul; J Stjernschantz; K No; C Liljebris; G Selén; M Astin; M Karlsson; L Z Bito
Journal:  J Med Chem       Date:  1993-01-22       Impact factor: 7.446

View more
  18 in total

1.  Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects.

Authors:  Ichiro Kawaguchi; Tomomi Higashide; Shinji Ohkubo; Chiaki Kawaguchi; Kazuhisa Sugiyama
Journal:  Jpn J Ophthalmol       Date:  2012-06-07       Impact factor: 2.447

2.  Efficacy of locally produced Latanoprost in the control of intraocular pressure in patients with primary open-angle glaucoma.

Authors:  Pir Salim Mahar; Nadeem H Butt; Syed Imtiaz Ali
Journal:  Int Ophthalmol       Date:  2017-12-05       Impact factor: 2.031

3.  Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients.

Authors:  Nicholas Brennan; Mohammad H Dehabadi; Sandhya Nair; Ana Quartilho; Catey Bunce; Ian Reekie; Raal Obikpo
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

4.  Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less.

Authors:  Tadashi Nakano; Keiji Yoshikawa; Tairo Kimura; Hirotaka Suzumura; Mami Nanno; Takahiko Noro
Journal:  Jpn J Ophthalmol       Date:  2011-08-27       Impact factor: 2.447

5.  Circadian changes of intraocular pressure and ocular perfusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucoma.

Authors:  Ciro Costagliola; Francesco Parmeggiani; Gianni Virgili; Giuseppe Lamberti; Carlo Incorvaia; Paolo Perri; Claudio Campa; Adolfo Sebastiani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-11-15       Impact factor: 3.117

6.  Effects of 0.2% brimonidine and 0.2% brimonidine-0.5% timolol on intraocular pressure and pupil size in normal equine eyes.

Authors:  M Von Zup; M Lassaline; P H Kass; P E Miller; S M Thomasy
Journal:  Equine Vet J       Date:  2017-06-05       Impact factor: 2.888

7.  A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).

Authors:  Kenneth W Olander; Michelle A Sato; Marc A Abrams; Gary W Jerkins; Fenghe Lu; Phillip Dinh; Noriko Odani-Kawabata; Almira Chabi; Naveed K Shams
Journal:  J Glaucoma       Date:  2021-06-01       Impact factor: 2.503

8.  Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events.

Authors:  Toyoaki Tsumura; Keiji Yoshikawa; Hirotaka Suzumura; Tairo Kimura; Satoshi Sasaki; Itaru Kimura; Ryuji Takeda
Journal:  Clin Ophthalmol       Date:  2012-09-21

Review 9.  Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension.

Authors:  Masato Matsuo; Yotaro Matsuoka; Masaki Tanito
Journal:  Clin Ophthalmol       Date:  2022-04-26

Review 10.  Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients.

Authors:  Ziyan Cai; Mengdan Cao; Ke Liu; Xuanchu Duan
Journal:  J Ophthalmol       Date:  2021-05-25       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.